Poschke Isabel C, Hassel Jessica C, Rodriguez-Ehrenfried Aaron, Lindner Katharina A M, Heras-Murillo Ignacio, Appel Lena M, Lehmann Johanna, Lövgren Tanja, Wickström Stina L, Lauenstein Claudia, Roth Jasmin, König Anna-Katharina, Haanen John B A G, van den Berg Joost, Kiessling Rolf, Bergmann Frank, Flossdorf Michael, Strobel Oliver, Offringa Rienk
Department of General Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Germany.
Clin Cancer Res. 2020 Aug 15;26(16):4289-4301. doi: 10.1158/1078-0432.CCR-19-3845. Epub 2020 Apr 17.
During our efforts to develop tumor-infiltrating lymphocyte (TIL) therapy to counter the devastating recurrence rate in patients with primary resectable pancreatic ductal adenocarcinoma (PDA), we found that PDA TILs can readily be expanded and that the majority of resulting TIL cultures show reactivity against the autologous tumor. However, the fraction of tumor-reactive T cells is low. We investigated to which extent this was related to the expansion.
We compared the clonal composition of TIL preparations before and after expansion using T-cell receptor (TCR) deep sequencing. Our findings for PDA were benchmarked to experiments with melanoma TILs.
We found that the TIL TCR repertoire changes dramatically during expansion, leading to loss of tumor- dominant T-cell clones and overgrowth by newly emerging T-cell clones that are barely detectable in the tumor. These changes are primarily driven by differences in the intrinsic expansion capacity of T-cell clones. Single-cell experiments showed an association between poor proliferative capacity and expression of markers related to antigen experience and dysfunction. Furthermore, we found that spatial heterogeneity of the TIL repertoire resulted in TCR repertoires that are greatly divergent between TIL cultures derived from distant tumor samples of the same patient.
Culture-induced changes in clonal composition are likely to affect tumor reactivity of TIL preparations. TCR deep sequencing provides important insights into the factors that govern the outcome of TIL expansion and thereby a path toward optimization of the production of TIL preparations with high therapeutic efficacy..
在我们开发肿瘤浸润淋巴细胞(TIL)疗法以应对原发性可切除胰腺导管腺癌(PDA)患者高复发率的过程中,我们发现PDA的TIL很容易扩增,并且大多数由此产生的TIL培养物显示出对自体肿瘤的反应性。然而,肿瘤反应性T细胞的比例很低。我们研究了这在多大程度上与扩增有关。
我们使用T细胞受体(TCR)深度测序比较了扩增前后TIL制剂的克隆组成。我们对PDA的研究结果与黑色素瘤TIL的实验进行了对比。
我们发现TIL的TCR库在扩增过程中发生了巨大变化,导致肿瘤主导的T细胞克隆丢失,而在肿瘤中几乎检测不到的新出现的T细胞克隆过度生长。这些变化主要是由T细胞克隆内在扩增能力的差异驱动的。单细胞实验表明增殖能力差与抗原经历和功能障碍相关标志物的表达之间存在关联。此外,我们发现TIL库的空间异质性导致来自同一患者远处肿瘤样本的TIL培养物之间的TCR库有很大差异。
培养诱导的克隆组成变化可能会影响TIL制剂的肿瘤反应性。TCR深度测序为控制TIL扩增结果的因素提供了重要见解,从而为优化具有高治疗效果的TIL制剂生产提供了一条途径。